- Home
- DYAI vs BEAT Comparison
DYAI vs BEAT Comparison
Compare DYAI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- BEAT
- Stock Information
- Founded
- DYAI 1979
- BEAT 2015
- Country
- DYAI United States
- BEAT United States
- Employees
- DYAI N/A
- BEAT N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- DYAI Health Care
- BEAT Technology
- Exchange
- DYAI Nasdaq
- BEAT Nasdaq
- Market Cap
- DYAI 54.4M
- BEAT 65.1M
- IPO Year
- DYAI 2004
- BEAT 2021
- Fundamental
- Price
- DYAI $1.47
- BEAT $2.08
- Analyst Decision
- DYAI Strong Buy
- BEAT Buy
- Analyst Count
- DYAI 1
- BEAT 1
- Target Price
- DYAI $6.00
- BEAT $8.00
- AVG Volume (30 Days)
- DYAI 41.8K
- BEAT 132.5K
- Earning Date
- DYAI 03-27-2025
- BEAT 03-19-2025
- Dividend Yield
- DYAI N/A
- BEAT N/A
- EPS Growth
- DYAI N/A
- BEAT N/A
- EPS
- DYAI N/A
- BEAT N/A
- Revenue
- DYAI $3,364,548.00
- BEAT N/A
- Revenue This Year
- DYAI $51.30
- BEAT N/A
- Revenue Next Year
- DYAI $73.26
- BEAT N/A
- P/E Ratio
- DYAI N/A
- BEAT N/A
- Revenue Growth
- DYAI 13.82
- BEAT N/A
- 52 Week Low
- DYAI $0.93
- BEAT $1.35
- 52 Week High
- DYAI $2.67
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- DYAI 44.17
- BEAT 39.34
- Support Level
- DYAI $1.35
- BEAT $2.05
- Resistance Level
- DYAI $1.60
- BEAT $2.37
- Average True Range (ATR)
- DYAI 0.14
- BEAT 0.18
- MACD
- DYAI -0.01
- BEAT -0.02
- Stochastic Oscillator
- DYAI 31.58
- BEAT 21.24
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.